OverviewSuggest Edit

Theravance Biopharma is a biopharmaceutical company which provides medicines to treat serious illnesses. It focuses on several therapeutic areas, including infectious disease, respiratory, gastrointestinal disease, and cardiovascular and renal disease.
TypePublic
Founded1996
HQDublin, IE
Websitetheravance.com
Employee Ratings3.5
Overall CultureB+

Latest Updates

Employees (est.) (Mar 2019)363(+7%)
Job Openings13
Revenue (FY, 2018)$60.4 M(+293%)
Share Price (Sept 2021)$8.5
Cybersecurity ratingAMore

Key People/Management at Theravance Biopharma

Rick Winningham

Rick Winningham

Chairman, Chief Executive Officer
Gary Barrera

Gary Barrera

Vice President
Eran Broshy

Eran Broshy

Director
Dennis O. Driver

Dennis O. Driver

Senior Vice President, Human Resources, Organizational and Leadership Development
Reigin Zawadzki

Reigin Zawadzki

Vice President, Human Resources
Robert V. Gunderson

Robert V. Gunderson

Director
Show more

Theravance Biopharma Office Locations

Theravance Biopharma has offices in Dublin and San Francisco
Dublin, IE (HQ)
Connaught House, 1 Burlington Rd
San Francisco, CA, US
901 Gateway Boulevard
Show all (2)

Theravance Biopharma Financials and Metrics

Theravance Biopharma Revenue

Embed Graph
View revenue for all periods
Theravance Biopharma's revenue was reported to be $60.37 m in FY, 2018 which is a 292.4% increase from the previous period.
USD

Revenue (FY, 2018)

60.4m

Revenue growth (FY, 2017 - FY, 2018), %

292.4%

Gross profit (FY, 2018)

59.7m

Gross profit margin (FY, 2018), %

98.8%

Net income (FY, 2018)

(215.5m)

EBIT (FY, 2018)

(238.8m)

Market capitalization (6-Sept-2021)

622.3m

Closing stock price (6-Sept-2021)

8.5

Cash (31-Dec-2018)

378.0m

EV

469.1m
Theravance Biopharma's current market capitalization is $622.3 m.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

48.6m15.4m60.4m

Revenue growth, %

(68%)292%

Cost of goods sold

2.9m6.0m715.0k

Gross profit

45.8m9.4m59.7m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

18.4m5.5m19.1m3.1m3.5m4.3m8.3m23.5m12.8m

Cost of goods sold

778.0k638.0k332.0k565.0k1.4m985.0k1.4m705.0k

Gross profit

17.6m4.8m18.7m2.5m2.1m3.3m22.0m12.1m

Gross profit Margin, %

96%88%98%82%61%77%94%95%
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

344.7m89.0m378.0m

Accounts Receivable

646.0k2.3m620.0k

Inventories

12.2m16.8m

Current Assets

528.5m378.7m532.8m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

128.8m148.4m86.6m169.9m139.6m91.3m125.8m103.9m101.2m

Accounts Receivable

1.5m1.9m873.0k1.2m1.3m1.6m2.0m3.4m3.0m

Inventories

9.4m9.8m12.5m13.2m12.1m15.3m17.2m17.9m17.9m

Current Assets

238.8m303.1m274.0m421.5m384.9m367.1m446.8m386.7m332.6m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(190.7m)(285.4m)(215.5m)

Depreciation and Amortization

3.1m4.0m3.2m

Inventories

(3.2m)(7.3m)(1.6m)

Accounts Payable

(16.4m)3.8m3.6m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(42.1m)(89.4m)(123.3m)(65.3m)(131.6m)(198.5m)(65.1m)(105.9m)(165.3m)

Depreciation and Amortization

699.0k1.2m1.9m1.1m2.1m3.0m900.0k1.7m2.3m

Inventories

134.0k157.0k(1.8m)140.0k(497.0k)(3.0m)(371.0k)(351.0k)(552.0k)

Accounts Payable

(9.4m)(10.8m)(12.8m)2.0m4.8m3.5m(449.0k)(2.3m)(1.7m)
USDQ1, 2016

Financial Leverage

1.2 x
Show all financial metrics

Theravance Biopharma Operating Metrics

FY, 2016FY, 2017FY, 2018Apr, 2019

Partners

6

Patents (Foreign)

1.68 k1.96 k1.67 k

Patents (US)

434459438
Show all operating metrics

Theravance Biopharma Acquisitions / Subsidiaries

Company NameDateDeal Size
Theravance Biopharma Antibiotics IP
Theravance Biopharma Ireland Limited
Theravance Biopharma R&D
Theravance Biopharma R&D IP
Theravance Biopharma UK Limited
Theravance Biopharma US
Triple Royalty Sub LLC

Theravance Biopharma Revenue Breakdown

Embed Graph

Theravance Biopharma revenue breakdown by geographic segment: 18.4% from Europe, 81.6% from US and 0.0% from Other

Theravance Biopharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Theravance Biopharma Online and Social Media Presence

Embed Graph

Theravance Biopharma Company Culture

  • Overall Culture

    B+

    75/100

  • CEO Rating

    A+

    80/100

  • Compensation

    D

    54/100

Learn more on Comparably

Theravance Biopharma News and Updates

Theravance Biopharma to Report Second Quarter 2021 Financial Results on August 3, 2021

DUBLIN, Ireland, July 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its second quarter 2021 financial results and...

Theravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary Shares

DUBLIN, June 24, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today the pricing of its...

Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19

DUBLIN and SOUTH SAN FRANCISCO, Calif., June 21, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective...

Theravance Biopharma to Participate in Upcoming Investor Conferences

DUBLIN, Feb. 10, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in investor events as follows: Management will be...

Theravance Biopharma, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update

DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the third quarter ending September 30, 2020. Theravance Biopharma's Total Revenue for the third quarter 2020 was $18.3 million....

Theravance Biopharma to Report Second Quarter 2020 Financial Results on August 6, 2020

DUBLIN, July 27, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its second quarter 2020 financial results and provide a...
Show more

Theravance Biopharma Blogs

Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio

Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio jo-en.bautista… Wed, 09/15/2021 - 06:06 Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio September 15, 2021 at 6:06 AM EDT …

Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension

Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension Content Import Wed, 09/15/2021 - 06:05 Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in …

Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis

- Randomized, double-blind, placebo-controlled study did not meet the primary endpoint: change in the total Mayo score at week eight, relative to placebo - Izencitinib was well-tolerated and safety data were consistent with expectations for this gut-selective pan-JAK inhibitor - Investor conference

Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update san.mai@intrado.com Tue, 08/03/2021 - 16:01 Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update August 3, 2021 at 4:00 PM E…

Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares

Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares Content Import Thu, 06/24/2021 - 16:34 Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares June 24, 2021 at 4:33 PM EDT This release is a backfill fro…

Theravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update

Theravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update san.mai@intrado.com Tue, 05/04/2021 - 16:09 Theravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update May 4, 2021 at 4:05 PM EDT …
Show more

Theravance Biopharma Frequently Asked Questions

  • When was Theravance Biopharma founded?

    Theravance Biopharma was founded in 1996.

  • Who are Theravance Biopharma key executives?

    Theravance Biopharma's key executives are Rick Winningham, Gary Barrera and Eran Broshy.

  • How many employees does Theravance Biopharma have?

    Theravance Biopharma has 363 employees.

  • What is Theravance Biopharma revenue?

    Latest Theravance Biopharma annual revenue is $60.4 m.

  • What is Theravance Biopharma revenue per employee?

    Latest Theravance Biopharma revenue per employee is $166.3 k.

  • Who are Theravance Biopharma competitors?

    Competitors of Theravance Biopharma include Acceleron Pharma, Inflazome and Prothena.

  • Where is Theravance Biopharma headquarters?

    Theravance Biopharma headquarters is located at Connaught House, 1 Burlington Rd, Dublin.

  • Where are Theravance Biopharma offices?

    Theravance Biopharma has offices in Dublin and San Francisco.

  • How many offices does Theravance Biopharma have?

    Theravance Biopharma has 2 offices.